FAST READ
- The Indian Pharmacopoeia Commission held a national conference on biosimilar quality and safety on 10-11 September 2026 at C-CAMP, Bengaluru.
- IPC launched an Indian Pharmacopoeia Reference Substance for Enoxaparin Sodium for bioassays.
- The conference brought together 160 participants from regulators, industry, academia and research organisations.
WHY IN NEWS
- Biosimilars can lower the cost of complex biologic therapies, but unlike simple generic drugs they require rigorous comparability, manufacturing and pharmacovigilance standards.
- The conference linked quality infrastructure with India's Biopharma SHAKTI vision of innovation, self-reliance and global competitiveness.
TOP DATA & FACTS
- The conference was held on 10-11 September 2026.
- The venue was the Centre for Cellular and Molecular Platforms, Bengaluru.
- IPC is an autonomous institution under the Ministry of Health and Family Welfare.
- About 160 participants attended.
- Participants included regulatory authorities.
- Industry representatives participated.
- Academia and research organisations were represented.
- IPC launched an Indian Pharmacopoeia Reference Substance for Enoxaparin Sodium.
- The reference substance is intended for bioassays.
- Biosimilars are highly similar to an already approved reference biological product.
- They are not treated as simple chemical generics because biologics are structurally complex.
- Quality control includes identity, purity, potency and consistency of manufacturing.
- Pharmacovigilance remains important after approval because rare or delayed adverse effects may emerge at scale.
- Reference standards support reproducible laboratory testing and comparability.
- Domestic reference materials can reduce dependence on imported analytical standards.
PRELIMS
- Indian Pharmacopoeia lays down standards for drugs and pharmaceutical substances used in India.
- IPC functions under the Union Ministry of Health and Family Welfare.
- Biosimilars are biological products, not conventional small-molecule generics.
- Reference standards are used in laboratory testing and quality control.
- Enoxaparin is a low-molecular-weight heparin used as an anticoagulant.
- Post-marketing pharmacovigilance remains relevant even after regulatory approval.